![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)
Sanofi sluit zijn vestigingen in Gouda en Naarden. De Franse farmaceut huisvest alle activiteiten en medewerkers in dit land voortaan op één locatie in Amsterdam, schrijft Het Financieele Dagblad.
Allergan aims to appease investors with non-core units sell off
Allergan’s share price has been on a steady downward trajectory for the last year and investors are becoming increasingly frustrated with the drugmaker’s attempts to turn it around.
ViiV’s two-drug regimen gets EU approval for HIV-1
ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the European Commission, making it the first available two-drug regimen, daily...
EMA review confirms risks of Abbvie and Biogen’s Zinbryta outweigh benefits
The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the treatment of multiple sclerosis (MS), do not outweigh its risks, following a review...
Novartis data at ASCO and EHA reinforce company’s commitment to reimagining cancer
Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 in Chicago; and the 23rd Annual Congress of the...
India, Sweden and The Netherlands form HIV/AIDS research partnership
A first-of-its-kind collaboration has been announced by the governments of India, Sweden and The Netherlands with the goal of advancing research in the treatment of HIV and AIDS by leveraging the “complementary research...
Pfizer’s Lyrica achieves endpoint as adjunct in paediatric epilepsy
Pfizer has revealed new Phase 3 data for its oral epilepsy therapy Lyrica (pregbalin) as an adjunctive treatment for partial onset seizures associated with the condition in paediatric patients aged from one month to...
Amgen/Novartis potential blockbuster migraine gets FDA nod
The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig is the first CGRP inhibitor to receive approval but won’t be the last, as a number of competitors wait...
Antibioticagebruik tijdens zwangerschap vergroot kans op astma bij kind
Resultaten van een grote populatiestudie laten zien dat gebruik van antibiotica tijdens de zwanger geassocieerd is met het optreden van astma. Het risico neemt toe naarmate de moeder meerdere kuren heeft geslikt tijdens...
Takeda begins to shore up finances with $280m divestment
Much has already been written about Takeda and its massive financial stretch to pull in the Shire acquisition, in the massive $62 billion deal.
J&J must pay $4 million in punitive damages in latest asbestos cancer trial
A California jury ordered Johnson & Johnson to pay $4 million in punitive damages to a woman who said she developed cancer after being exposed to asbestos in the company’s baby powder, pushing the total...
AZ’s Imfinzi hits second major milestone at Phase 3 in unresectable lung cancer
AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi (durvalumab) in the treatment of unresectable Stage III non-small cell lung cancer...
BioMarin receives FDA nod for its would-be blockbuster
BioMarin is confident that its newly approved treatment for phenylketonuria (PKU) is set to become a blockbuster and it’s priced the drug accordingly, at $488 per unit.
GDPR: welk risico lopen bedrijven écht?
In de afgelopen dagen zijn we allemaal murw geslagen door een schier eindeloze stroom van GDPR-mailtjes. Veel bedrijven vragen zich ondertussen vertwijfeld af of zij niet ook zulke mails zouden moeten versturen.
Radboudumc zet nieuwe uitkomsten oncologiezorg online
Het Radboudumc Centrum voor Oncologie heeft nieuwe uitkomsten voor ruim twintig soorten kanker online gezet. Bij alle kankersoorten zijn cijfers over aantallen behandelingen, wacht- en doorlooptijden...
Astellas begins major restructure, as 600 jobs slashed
Astellas, under the direction of new CEO, Kenji Yasukawa, has unveiled a major new restructure, ahead of a difficult looking year financially in 2019.
Waarom competitive intelligence een must is voor je onlinemarketingstrategie
Veel online marketeers zouden tekenen voor 25% online groei binnen een half jaar. Als je hieraan toevoegt dat de concurrentie ondertussen groeit met 75%, dan denken ze wel twee keer na. Het vergroten van beschikbare...
Ook geneesmiddelenonderzoek met Nivel Zorgregistraties
Met Nivel Zorgregistraties houden we bij hoe vaak ziekten voorkomen in Nederland, zoals griep, diabetes en hart- en vaatziekten. Maar we kunnen met deze gegevens ook geneesmiddelenbeleid evalueren, veranderingen in...
